Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Verapamil in CF-related Dysglycemia
NCT07688070Phase 2Not yet recruiting
- Sponsor
- Rhode Island Hospital
- Start
- Aug 2026
- Primary completion
- Jul 2028
- Countries
- 1
01
Overview
A Phase 2 trial of verapamil in cystic fibrosis-related diabetes (CFRD), impaired glucose tolerance (IGT), sponsored by Rhode Island Hospital. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
verapamil
03
Conditions
cystic fibrosis-related diabetes (CFRD)impaired glucose tolerance (IGT)
Beyond the preview
Go deeper on NCT07688070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07688070.